**Article title:** Establishment and Application of an Index System for the Risk of Drug Shortages in China: Based on Delphi Method and Analytic Hierarchy Process.

Journal name: International Journal of Health Policy and Management (IJHPM)

**Authors' information**: Yin Shi<sup>1,2,3,4</sup>, Shusen Sun<sup>1,2,3,4,5</sup>, Jing Deng<sup>6</sup>, Shao Liu<sup>1,2,3,4</sup>, Tao Yin<sup>1,2,3,4</sup>, Qilin Peng<sup>1,2,3,4</sup>, Zhicheng Gong<sup>1,2,3,4</sup>, Zihua Cheng<sup>2,3,7</sup>, Boting Zhou<sup>1,2,3,4\*</sup>

(Corresponding author: botingzhou0918@126.com)

Supplementary file 2. Contains Table S6-Table S7

Table S6: Judgment matrix and consistency test of the indexes

Table S7: The characteristics of drugs at different risk levels

<sup>&</sup>lt;sup>1</sup> Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.

<sup>&</sup>lt;sup>2</sup> National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

<sup>&</sup>lt;sup>3</sup> Hunan Drug Shortage Surveillance and Early Warning Center, Changsha, China.

<sup>&</sup>lt;sup>4</sup> The Hunan Institute of Pharmacy Practice and Clinical Research, Changsha, China.

<sup>&</sup>lt;sup>5</sup> Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Western New England University, Springfeld, MA, USA.

<sup>&</sup>lt;sup>6</sup> Department of Epidemiology and Health Statistics, XiangYa School of Public Health, Central South University, Changsha, China.

<sup>&</sup>lt;sup>7</sup> Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.

Table S6 Judgment matrix and consistency test of the indexes

Judgment m	atrix of fir	st-level ind	exes (A1 Ph	narmaceutica	al properties	s, A2 Supply	y stability, <i>A</i>	A3 Drug acc	essibility, A	4 Causes of	shortage)				
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0909	0.0806	0.0039	0.0618	0.0790	0.0676	0.0227	0.0891	0.0771	0.0806	0.0866	0.0989	0.0675	0.0413	0.0039
λmax	4.2428	4.2153	4.0104	4.1649	4.2109	4.1806	4.0606	4.2379	4.2059	4.2153	4.2314	4.2640	4.1801	4.1102	4.0104
Judgment m	atrix of sec	cond-level i	ndexes (B1	Essential dı	rug classific	ation, B2 S <sub>l</sub>	pecial classi	fication, B3	Availability	or alternativ	es, B4 Clinio	cally necessar	ry)		
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0287	0.0769	0.0813	0.0023	0.0790	0.0227	0.0880	0.0822	0.0940	0.0789	0.0328	0.0000	0.0909	0.0429	0.0766
λmax	4.0766	4.2053	4.2171	4.0062	4.2109	4.0606	4.2350	4.2194	4.2510	4.2106	4.0876	4.0000	4.2428	4.1145	4.2046
T-1	- 4 · · · · · · · · · · · · · · · · · ·	1 1 1 .		D- 1' (	C 1 4 1	L- D.C.C	C 1	1. D7.N	1 6	C 4					
Judgment m Consistency test	atrix of sec Expert 1	cond-level i Expert 2	ndexes (B5 Expert 3	Duration of Expert 4	- 11		e of short su Expert 7	pply, B7 Nu Expert 8	umber of ma	anufacturers i Expert 10	n province) Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
Consistency								11 0				Expert 12 0.0279	Expert 13 0.0176	Expert 14 0.0961	Expert 15 0.0000
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11				
Consistency test  CR	Expert 1  0.0053 3.0055	0.0825 3.0858	Expert 3  0.0000 3.0000	Expert 4  0.0088  3.0092	Expert 5  0.0961 3.0999	Expert 6  0.0000  3.0000	0.0000 3.0000	Expert 8  0.0904 3.0940	0.0904 3.0940	Expert 10 0.0624 3.0649	Expert 11  0.0370 3.0385	0.0279 3.0291	0.0176 3.0183	0.0961 3.0999	0.0000 3.0000
Consistency test CR λmax  Judgment m	Expert 1  0.0053 3.0055	0.0825 3.0858	Expert 3  0.0000 3.0000	Expert 4  0.0088  3.0092	Expert 5  0.0961 3.0999	Expert 6  0.0000  3.0000	0.0000 3.0000	Expert 8  0.0904 3.0940	0.0904 3.0940	Expert 10 0.0624 3.0649	Expert 11  0.0370 3.0385	0.0279 3.0291	0.0176 3.0183	0.0961 3.0999	0.0000 3.0000 encing drug
Consistency test  CR  λmax  Judgment m shortages)	0.0053 3.0055 atrix of sec	0.0825 3.0858 cond-level i	0.0000 3.0000 indexes (B8	0.0088 3.0092 3 Number of	Expert 5  0.0961 3.0999  f medical in	Expert 6  0.0000 3.0000 stitutions or	0.0000 3.0000 distribution	0.0904 3.0940 a enterprises	0.0904 3.0940 s experienci	0.0624 3.0649 ing drug shor	Expert 11  0.0370  3.0385  tages, B9 Ca	0.0279 3.0291 ategories of n	0.0176 3.0183	0.0961 3.0999 utions experie	0.0000 3.0000 encing drug
Consistency test  CR  λmax  Judgment m shortages)  Consistency	0.0053 3.0055 atrix of sec	0.0825 3.0858 cond-level i	0.0000 3.0000 indexes (B8	0.0088 3.0092 3 Number of	Expert 5  0.0961 3.0999  f medical in	Expert 6  0.0000 3.0000 stitutions or	0.0000 3.0000 distribution	0.0904 3.0940 a enterprises	0.0904 3.0940 s experienci	0.0624 3.0649 ing drug shor	Expert 11  0.0370  3.0385  tages, B9 Ca	0.0279 3.0291 ategories of n	0.0176 3.0183	0.0961 3.0999 utions experie	0.0000 3.0000

Judgment matrix of second-level indexes (B10 Supply related causes, B11 Demand related causes)

Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
λmax	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000
Judgment m	atrix of thi	rd-level inc	lexes (C1 E	ssential dru	gs, C2 None	essential dru	ıgs)								
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
λmax	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000
Judgment m	atrix of thi	rd-level ind	lexes (C3 E	mergency d	rugs, C4 De	etoxification	drugs, C5 I	Orugs for ra	re diseases,	C6 Other dr	ugs)				
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0204	0.0963	0.0123	0.0312	0.0826	0.0227	0.0123	0.0940	0.0163	0.0212	0.0888	0.0397	0.0822	0.0339	0.0123
λmax	4.0544	4.2572	4.0328	4.0833	4.2206	4.0606	4.0328	4.2509	4.0435	4.0566	4.2371	4.1061	4.2194	4.0905	4.0328
Judgment m	atrix of thi	rd-level ind	lexes (C7 A	lternative ex	xists, C8 Fu	ll alternativ	e does not e	xist, C9 No	alternative)	)					
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0772	0.0516	0.0904	0.0685	0.0707	0.0685	0.0904	0.0707	0.0772	0.0311	0.0904	0.0772	0.0707	0.0685	0.0685
λmax	3.0803	3.0536	3.0940	3.0713	3.0735	3.0713	3.0940	3.0735	3.0803	3.0324	3.0940	3.0803	3.0735	3.0713	3.0713
Judgment m	atrix of thi	ird-level in	dexes (C10	Diagnose a	nd treat disc	eases that ar	e life-threat	ening or se	riously imp	air quality of	life, C11 Li	fe-sustaining	, cure disease	or delay pro	ogression of
the disease si			`	Ŭ				·	• •		•			• •	·
Consistency	Expert 1		Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	·	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test	F	r · · -	r	r	r	r	r	1	1	1	1	1	1	1	1
CR	0.0336	0.0904	0.0036	0.0707	0.0355	0.0176	0.0036	0.0624	0.0000	0.0516	0.0904	0.0176	0.0370	0.0516	0.0036
	0.0330	0.070 <del>1</del>	0.0030	0.0707	0.0555	0.0170	0.0030	J.UU2 <del>T</del>	3.0000	0.0510	0.070 <del>1</del>	0.0170	0.0370	0.0510	0.0030

λmax	3.0349	3.0940	3.0037	3.0735	3.0369	3.0183	3.0037	3.0649	3.0000	3.0536	3.0940	3.0183	3.0385	3.0536	3.0037
Judgment m	atrix of thi	rd-level inc	dexes (C13	Time of sho	rt supply >6	6 months, C	14 Time of s	short supply	>3 months	. C15 Time o	of short suppl	v >1 months)	)		
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6			Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 1
test															
CR	0.0516	0.0336	0.0176	0.0036	0.0772	0.0685	0.0370	0.0516	0.0772	0.0707	0.0088	0.0068	0.0624	0.0772	0.0176
λmax	3.0536	3.0349	3.0183	3.0037	3.0803	3.0713	3.0385	3.0536	3.0803	3.0735	3.0092	3.0070	3.0649	3.0803	3.0183
Judgment m	Judgment matrix of third-level indexes (C16 Cities with short supply ≤5, C17 Cities with short supply >5)														
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 1
test															
CR	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
λmax	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000
Judgment ma	atrix of thi	rd-level in	dexes (C18	Manufactur	ed solely, C	19 Number	of manufact	urers ≥2)							
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 1
test															
CR	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
λmax	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000	2.0000
Judgment m			`					•	•	·			of medical in	stitutions or	distributio
enterprises ex	periencing	- 11	y between 6	and 10, C2	2 Number o	of medical in	nstitutions of			s experiencir	ng short supp	ly>10)			
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 1

Judgment matrix of third-level indexes (C23 All are primary health care institutions, C24 All are secondary health care institutions, C25 All are tertiary health care institutions, C26 Primary

0.0904

3.0940

0.0176

3.0183

0.0000

3.0000

0.0068

3.0070

0.0624

3.0649

0.0624

3.0649

0.0685

3.0713

0.0068

3.0070

0.0068

3.0070

test CR

λmax

0.0772

3.0803

0.0068

3.0070

0.0825

3.0858

0.0772

3.0803

0.0707

3.0735

0.0624

3.0649

and secondary/tertiary health care institutions, C27 Secondary and tertiary health care institutions, C28 Primary, secondary, and tertiary health care institutions)															
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0878	0.0969	0.0211	0.0645	0.0946	0.0979	0.0348	0.0963	0.0935	0.0723	0.0798	0.0623	0.0908	0.0513	0.0211
λmax	6.5529	6.6108	6.1332	6.4062	6.5960	6.6166	6.2193	6.6065	6.5892	6.4557	6.5030	6.3926	6.5721	6.3232	6.1332
Judgment matrix of third-level indexes (C29 Geographical remoteness, C30 Renovation of production line, C31 Shortage of raw materials, C32 Monopoly of raw materials)															
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0992	0.0981	0.0123	0.0665	0.0790	0.0854	0.0123	0.0945	0.0895	0.0976	0.0900	0.0444	0.0822	0.0981	0.0123
λmax	4.2650	4.2620	4.0328	4.1776	4.2109	4.2280	4.0328	4.2524	4.2389	4.2606	4.2404	4.1184	4.2195	4.2620	4.0328
Judgment ma	atrix of thi	rd-level inc	dexes (C33	Trading wit	h low price,	C34Low cl	inical dema	nd, C35 Fai	lure of bid	or bid rejection	on, C36Limit	t order)			
Consistency	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8	Expert 9	Expert 10	Expert 11	Expert 12	Expert 13	Expert 14	Expert 15
test															
CR	0.0454	0.0933	0.0000	0.0172	0.0922	0.0454	0.0000	0.0845	0.0000	0.0806	0.0806	0.0000	0.0295	0.0806	0.0000
λmax	4.1213	4.2492	4.0000	4.0458	4.2463	4.1213	4.0000	4.2257	4.0000	4.2153	4.2153	4.0000	4.0788	4.2153	4.0000

Table S7 The characteristics of drugs at different risk levels

	Total(n=383)	High risk <sup>a</sup> (n=6)	Medium risk <sup>b</sup> (n=39)	Low risk <sup>c</sup> (n=338)
Essential drug classificat	tion	(11 0)	11011 (II 07)	(ii 000)
Essential drugs	208 (54.31%)	4 (66.67%)	30 (76.92%)	174 (51.48%)
Nonessential drugs	175 4(5.69%)	2 (33.33%)	9 (23.08%)	164 (48.52%)
Special classification	175 (6.0570)	2 (33.3374)	(23.0070)	101 (10.0270)
Emergency drugs	38 (9.92%)	3 (50.00%)	5 (12.82%)	30 (8.88%)
Detoxification drugs	0	0	0	0
Drugs for rare diseases	0	0	0	0
Other drugs	345 (90.08%)	3 (50.00%)	34 (87.18%)	308 (91.12%)
Availability or alternativ	` ,	3 (30.0070)	31 (07.1070)	500 (51.1270)
Alternative exists	371 (96.87%)	4 (66.67%)	35 (89.74%)	332 (98.22%)
Full alternative does not	10 (2.61%)	0 (33.33%)	4 (10.26%)	6 (1.78%)
exist	10 (2.0170)	0 (33.3370)	(10.2070)	0 (1.7070)
No alternative	2 (0.52%)	2	0	0
Duration of short supply	` /	2	·	v
Time of short supply $\geq 6$	123 (32.11%)	6 (100.00%)	29 (74.36%)	88 (26.04%)
months	123 (32.1170)	0 (100.0070)	25 (71.3070)	00 (20.0170)
Time of short supply $\geq 3$	91 (23.76%)	0	5 (12.82%)	86 (25.44%)
months	71 (23.7070)	O	3 (12.0270)	00 (23.4470)
Time of short supply $\geq 1$	169 (44.13%)	0	5 (12.82%)	164 (48.52%)
months	107 (44.1570)	O	3 (12.0270)	104 (40.5270)
Scope of short supply				
Cities with short supply	350 (91.38%)	0	17 (43.59%)	333 (98.52%)
≤5	330 (71.3070)	O	17 (43.3770)	333 (70.3270)
Cities with short	33 (8.62%)	6 (100%)	22 (56.41%)	5 (1.48%)
supply >5	33 (0.0270)	0 (10070)	22 (30.4170)	3 (1.4070)
Number of manufacture	rs in province			
Manufactured solely	61 (15.93%)	1 (16.67%)	4 (10.26%)	56 (16.57%)
Number of	322 (84.07%)	,	,	282 (83.43%)
manufacturers ≥2	322 (04.0770)	3 (03.3370)	33 (07.7470)	202 (03.4370)
Number of medical insti-	tutions or distrik	uition enternri	ses evneriencing	drug shortages
Medical institutions or	340 (88.77%)	0	9 (23.08%)	331 (97.93%)
distribution enterprises	340 (00.7770)	O	7 (23.0070)	331 (77.7370)
experiencing short				
supply ≤5				
Medical institutions or	29 (7.57%)	0	22 (56.41%)	7 (2.07%)
distribution enterprises	27 (1.3170)	O	22 (30.7170)	7 (2.0770)
experiencing short				
supply between 6-10				
Medical institutions or	14 (3.66%)	6 (100%)	8 (20.51%)	0
	17 (3.00/0)	0 (100/0)	0 (20.3170)	U
distribution enterprises				
experiencing short				
supply >10				

Categories of medical institutions experiencing drug shortages											
All are primary health	120 (34.19%)	0	0	120 (38.71%)							
care institutions											
All are secondary health	67 (19.09%)	0	2 (5.71%)	65 (20.97%)							
care institutions											
All are tertiary health	69 (19.66%)	0	3 (8.57%)	66 (21.29%)							
care institutions											
Primary and secondary	38 (10.83%)	0	7 (20%)	31 (10.00%)							
health care institutions											
Secondary and tertiary	38 (10.83%)	3 (50%)	12 (34.29%)	23 (7.42%)							
health care institutions											
Primary, secondary, and	19 (5.41%)	3 (50%)	11 (31.43%)	5 (1.61%)							
tertiary health care											
institutions											

<sup>&</sup>lt;sup>a</sup> High risk represented the drug with a shortage risk score between 70-100 points.

<sup>b</sup> Medium risk represented the drug with a shortage risk score between 40-69 points.

<sup>&</sup>lt;sup>c</sup> Low risk represented the drug with a shortage risk score between 0-39 points.